Funding for this research was provided by:
Ontario Institute for Cancer Research (Clinician Scientist Grant)
London Health Sciences Foundation (N/A; philanthropic donations)
Text and Data Mining valid from 2019-08-19
Received: 2 February 2019
Accepted: 24 July 2019
First Online: 19 August 2019
Ethics approval and consent to participate
: Ethics approval has been obtained from the Ontario Cancer Research Ethics Board (#1697). Written consent to participate will be obtained from individual study participants and will include consent to undergo study interventions as well as biomarker assessment. Sample consent form is in Additional file InternalRef removed . Consent will be obtained at individual participating institutions by study investigators or clinical trials staff members.
: Not applicable
: RO has received grant funding from Varian Medical Systems, unrelated to this research project. DS has received grant funding from Varian Medical Systems Inc, and honoraria from AstraZeneca, Bayer, and Merck, unrelated to this research project. AVL has received honoraria from Varian Medical Systems and AstraZeneca, unrelated to this research project. SSenan has received grant funding from ViewRay and Varian Medical Systems, and honoraria from AstraZeneca, Celgene, and MSD, unrelated to this research project. The other authors declare that they have no competing interests.